[10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future].
Identifieur interne : 001276 ( PubMed/Corpus ); précédent : 001275; suivant : 001277[10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future].
Auteurs : M. PeschanskiSource :
- Journal de la Societe de biologie [ 1295-0661 ] ; 2001.
English descriptors
- KwdEn :
- Animals, Brain Tissue Transplantation, Cells, Cultured (transplantation), Combined Modality Therapy, Cricetinae, Fetal Tissue Transplantation, Forecasting, France, Humans, Huntington Disease (therapy), Levodopa (therapeutic use), Neurodegenerative Diseases (therapy), Neurons (transplantation), Parkinson Disease (drug therapy), Parkinson Disease (therapy), Rabbits, Rats, Species Specificity, Stem Cell Transplantation, Swine, Tissue and Organ Procurement, Transplantation, Heterologous, Transplantation, Homologous, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Levodopa.
- geographic : France.
- drug therapy : Parkinson Disease.
- therapy : Huntington Disease, Neurodegenerative Diseases, Parkinson Disease.
- transplantation : Cells, Cultured, Neurons.
- Animals, Brain Tissue Transplantation, Combined Modality Therapy, Cricetinae, Fetal Tissue Transplantation, Forecasting, Humans, Rabbits, Rats, Species Specificity, Stem Cell Transplantation, Swine, Tissue and Organ Procurement, Transplantation, Heterologous, Transplantation, Homologous, Treatment Outcome.
Abstract
Fetal neural allografts have already proven their therapeutic value in several hundreds of patients with Parkinson's disease, and have very recently provided promising results for patients with Huntington's disease in our center. Fetal neurons integrate readily into the neural parenchyma of the adult hosts, differentiate into mature neurons and substitute, anatomically and functionally for lost host neurons. Notable clinical improvements have been obtained using this procedure. Nevertheless, a major obstacle hampers the development of the technique, that provoked by the logistic difficulty in retrieving and preparing the tissue. Indeed, this requires, for each surgical session, the organization of a chain of expertise which cannot be taken up by an external provider (e.g. a biotech company). This is difficult to organize outside of specialized research centers. The future of the technique relies, therefore, upon the design of alternative sources of tissue. Two different ways are currently explored very actively, namely xenografting of neurons of porcine origin and human stem cells, in particular derived from ES cells. In both cases, but in different ways, the goal of both techniques is to allow the organisation of cell banking systems, relieving the constraints of obtaining the collaboration of specialized obstetricians and biologists. Obstacles foreseen for these two alternative ways of fetal neurons to be are identified and research laboratories are actively exploring ways to overcome them.
PubMed: 11530501
Links to Exploration step
pubmed:11530501Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future].</title><author><name sortKey="Peschanski, M" sort="Peschanski, M" uniqKey="Peschanski M" first="M" last="Peschanski">M. Peschanski</name><affiliation><nlm:affiliation>INSERM U421, IM3, Neuroplasticité et Thérapeutique, Faculté de Médecine, Créteil 94010.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11530501</idno><idno type="pmid">11530501</idno><idno type="wicri:Area/PubMed/Corpus">001276</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001276</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future].</title><author><name sortKey="Peschanski, M" sort="Peschanski, M" uniqKey="Peschanski M" first="M" last="Peschanski">M. Peschanski</name><affiliation><nlm:affiliation>INSERM U421, IM3, Neuroplasticité et Thérapeutique, Faculté de Médecine, Créteil 94010.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal de la Societe de biologie</title><idno type="ISSN">1295-0661</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Brain Tissue Transplantation</term><term>Cells, Cultured (transplantation)</term><term>Combined Modality Therapy</term><term>Cricetinae</term><term>Fetal Tissue Transplantation</term><term>Forecasting</term><term>France</term><term>Humans</term><term>Huntington Disease (therapy)</term><term>Levodopa (therapeutic use)</term><term>Neurodegenerative Diseases (therapy)</term><term>Neurons (transplantation)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (therapy)</term><term>Rabbits</term><term>Rats</term><term>Species Specificity</term><term>Stem Cell Transplantation</term><term>Swine</term><term>Tissue and Organ Procurement</term><term>Transplantation, Heterologous</term><term>Transplantation, Homologous</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Huntington Disease</term><term>Neurodegenerative Diseases</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Cells, Cultured</term><term>Neurons</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Brain Tissue Transplantation</term><term>Combined Modality Therapy</term><term>Cricetinae</term><term>Fetal Tissue Transplantation</term><term>Forecasting</term><term>Humans</term><term>Rabbits</term><term>Rats</term><term>Species Specificity</term><term>Stem Cell Transplantation</term><term>Swine</term><term>Tissue and Organ Procurement</term><term>Transplantation, Heterologous</term><term>Transplantation, Homologous</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Fetal neural allografts have already proven their therapeutic value in several hundreds of patients with Parkinson's disease, and have very recently provided promising results for patients with Huntington's disease in our center. Fetal neurons integrate readily into the neural parenchyma of the adult hosts, differentiate into mature neurons and substitute, anatomically and functionally for lost host neurons. Notable clinical improvements have been obtained using this procedure. Nevertheless, a major obstacle hampers the development of the technique, that provoked by the logistic difficulty in retrieving and preparing the tissue. Indeed, this requires, for each surgical session, the organization of a chain of expertise which cannot be taken up by an external provider (e.g. a biotech company). This is difficult to organize outside of specialized research centers. The future of the technique relies, therefore, upon the design of alternative sources of tissue. Two different ways are currently explored very actively, namely xenografting of neurons of porcine origin and human stem cells, in particular derived from ES cells. In both cases, but in different ways, the goal of both techniques is to allow the organisation of cell banking systems, relieving the constraints of obtaining the collaboration of specialized obstetricians and biologists. Obstacles foreseen for these two alternative ways of fetal neurons to be are identified and research laboratories are actively exploring ways to overcome them.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11530501</PMID><DateCreated><Year>2001</Year><Month>09</Month><Day>03</Day></DateCreated><DateCompleted><Year>2001</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1295-0661</ISSN><JournalIssue CitedMedium="Print"><Volume>195</Volume><Issue>1</Issue><PubDate><Year>2001</Year></PubDate></JournalIssue><Title>Journal de la Societe de biologie</Title><ISOAbbreviation>J. Soc. Biol.</ISOAbbreviation></Journal><ArticleTitle>[10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future].</ArticleTitle><Pagination><MedlinePgn>51-5</MedlinePgn></Pagination><Abstract><AbstractText>Fetal neural allografts have already proven their therapeutic value in several hundreds of patients with Parkinson's disease, and have very recently provided promising results for patients with Huntington's disease in our center. Fetal neurons integrate readily into the neural parenchyma of the adult hosts, differentiate into mature neurons and substitute, anatomically and functionally for lost host neurons. Notable clinical improvements have been obtained using this procedure. Nevertheless, a major obstacle hampers the development of the technique, that provoked by the logistic difficulty in retrieving and preparing the tissue. Indeed, this requires, for each surgical session, the organization of a chain of expertise which cannot be taken up by an external provider (e.g. a biotech company). This is difficult to organize outside of specialized research centers. The future of the technique relies, therefore, upon the design of alternative sources of tissue. Two different ways are currently explored very actively, namely xenografting of neurons of porcine origin and human stem cells, in particular derived from ES cells. In both cases, but in different ways, the goal of both techniques is to allow the organisation of cell banking systems, relieving the constraints of obtaining the collaboration of specialized obstetricians and biologists. Obstacles foreseen for these two alternative ways of fetal neurons to be are identified and research laboratories are actively exploring ways to overcome them.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peschanski</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>INSERM U421, IM3, Neuroplasticité et Thérapeutique, Faculté de Médecine, Créteil 94010.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Dix ans de traitement substitutif de maladies neurodégénératives par greffe de neurones foetaux: un bilan positif mais des interrogations sur l'avenir.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>J Soc Biol</MedlineTA><NlmUniqueID>100890617</NlmUniqueID><ISSNLinking>1295-0661</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016380" MajorTopicYN="Y">Brain Tissue Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016332" MajorTopicYN="Y">Fetal Tissue Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033581" MajorTopicYN="N">Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009927" MajorTopicYN="N">Tissue and Organ Procurement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014183" MajorTopicYN="N">Transplantation, Heterologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>9</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>10</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>9</Month><Day>4</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11530501</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001276 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001276 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:11530501
|texte= [10 years of substitution therapy for neurodegenerative diseases using fetal neuron grafts: a positive outcome but with questions for the future].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:11530501" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |